T CELL DEPLETION WITH ANTI-CD5 IMMUNOTOXIN IN HISTOCOMPATIBLE BONE MARROW TRANSPLANTATION
- 1 September 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 50 (3), 410-414
- https://doi.org/10.1097/00007890-199009000-00011
Abstract
Twenty-nine patients with advanced leukemias (median age 34 years) received histocompatible sibling marrow that had been depleted of T cells by ex vivo incubation with anti-CD5 monoclonal antibody-ricin immunotoxin (T101-R) for the purpose of graft-versus-host disease prophylaxis. Donor cell engraftment was documented in 28/29 patients by DNA restriction fragment length polymorphisms. In this pilot study the dose of T101-R incubated with donor marrow was increased in a stepwise manner from 300 ng (10 patients) to 600 ng (5 patients) to 1000 ng immunotoxin (IT)/107 bone marrow mononuclear cells (14 patients) in an attempt to achieve more effective GvHD prophylaxis. A statistically significant reduction in acute GvHD was achieved for patients receiving marrow pretreated with 1000 ng of immunotoxin (34%) compared to recipients of BM treated with 300 ng immunotoxin (100%, P = 0.0004). T-depleted marrow samples were evaluated for residual T cell activity using several in vitro assays including proliferation to the purified mitogen PHA (HA-17) and in mixed lymphocyte culture (MLC), T cell cytotoxicity, a limiting dilution assay for detecting precursors of proliferating T cells (LDApPTL), and phenotypic analysis of viable T cells expanded in 16-day culture with interleukin 2. The extent of T cell depletion determined by LDA assay varied widely at each immunotoxin concentration used. Thus, there was no corelation between the dose of T cells infused and subsequent GvHD. Phenotyping of lymphocytes recovered from immunotoxin-treated marrow demonstrated that residual T cells were CD5 negative in all cases tested. The only in vitro parameter that predicted subsequent acute or chronic GvHD was the demonstration of viable CD5 negative lymphocytes with T cell phenotype (CD2, CD3, and/or CD7 positive) after 16-day culture with IL-2 of the T-depleted bone marrow. We observed that such CD5 negative cells expressing other T cell markers have cytotoxic function and speculate that these cells may be capable of mediating GvHD in allogeneic transplantation.This publication has 11 references indexed in Scilit:
- FUNCTIONAL AND PHENOTYPICAL STUDIES OF THE LEU-4 (CD3)+, LEU-1 (CD5)- LYMPHOCYTE-T1988
- Phenotypic and functional characterization of human cytolytic T cells lacking expression of CD5.Journal of Clinical Investigation, 1988
- GRAFT-VERSUS-HOST DISEASE PREVENTION IN ALLOGENEIC BONE MARROW TRANSPLANTATION FROM HISTOCOMPATIBLE SIBLINGS A PILOT STUDY USING IMMUNOTOXINS FOR T CELL DEPLETION OF DONOR BONE MARROWTransplantation, 1987
- GRAFT-VERSUS-HOST DISEASE FOLLOWING TRANSPLANTATION OF ONE LOG VERSUS 2 LOG T-LYMPHOCYTE-DEPLETED BONE-MARROW FROM HLA-IDENTICAL DONORS1986
- CLONABLE LYMPHOCYTES-T IN T-CELL-DEPLETED BONE-MARROW TRANSPLANTS CORRELATE WITH DEVELOPMENT OF GRAFT-V-HOST DISEASE1986
- Interstitial Pneumonitis After Bone Marrow TransplantationAnnals of Internal Medicine, 1986
- RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS AS MARKERS OF ENGRAFTMENT IN ALLOGENEIC MARROW TRANSPLANTATION1985
- EX-VIVO TREATMENT OF DONOR BONE MARROW WITH ANTI-T-CELL IMMUNOTOXINS FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASEThe Lancet, 1984
- Anti-T-Cell Reagents for Human Bone Marrow Transplantation: Ricin Linked to Three Monoclonal AntibodiesScience, 1983
- Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.The Journal of Immunology, 1981